A phase 2a multiple ascending dose, safety and tolerability study of PK051.
Latest Information Update: 27 Sep 2023
At a glance
- Drugs PK 051 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors PharmaKure
Most Recent Events
- 27 Sep 2023 New trial record